I reported previously (see here) on Israel’s Entera Bio and its treatment for hypoparathyroidism. Entera Bio has just signed a research and licensing agreement with US multinational Amgen to develop a new oral molecule-based treatment that currently is given via IV or injection.

https://investors.enterabio.com/news-releases/news-release-details/entera-bio-and-amgen-enter-strategic-research-collaboration

https://www.enterabio.com/